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ph receptors and their ligands (ephrins) play an impor-
tant role in axonal guidance, topographic mapping, and
angiogenesis. The signaling pathways mediating these
activities are starting to emerge and are highly cell- and
receptor-type speciﬁc. Here we demonstrate that activated
 
EphB1 recruits the adaptor proteins Grb2 and p52
 
Shc
 
 and
promotes p52
 
Shc
 
 and c-Src tyrosine phosphorylation as
well as MAPK/extracellular signal–regulated kinase (ERK)
activation. EphB1-mediated increase of cell migration was
abrogated by the MEK inhibitor PD98059 and Src inhibitor
PP2. In contrast, cell adhesion, which we previously
showed to be c-jun NH2-terminal kinase (JNK) dependent,
E
 
was unaffected by ERK1/2 and Src inhibition. Expression
of dominant-negative c-Src signiﬁcantly reduced EphB1-
dependent ERK1/2 activation and chemotaxis. Site-directed
mutagenesis experiments demonstrate that tyrosines 600
and 778 of EphB1 are required for its interaction with c-Src
and p52
 
Shc
 
. Furthermore, phosphorylation of p52
 
Shc
 
 by c-Src
is essential for its recruitment to EphB1 signaling com-
plexes through its phosphotyrosine binding domain. Together
these ﬁndings highlight a new aspect of EphB1 signaling,
whereby the concerted action of c-Src and p52
 
Shc
 
 activates
MAPK/ERK and regulates events involved in cell motility.
 
Introduction
 
Angiogenesis and axonal guidance are complex processes
necessitating a tightly regulated temporal and spatial control.
In the past years, Eph receptors and their membrane-bound
ligands (ephrins) have emerged as key players in these crucial
events, as demonstrated by several genetic studies in mice.
Mutant animals lacking ephrinB2 or EphB4 die before day
11 of embryonic development displaying various cardio-
vascular defects (Wang et al., 1998; Adams et al., 1999).
Targeted mutation of the EphB2 gene in mice revealed a
profound defect in the pathfinding of a specific axon tract of
the anterior commissure (Henkemeyer et al., 1996). Recently,
Eph receptors have also been shown to regulate synapse for-
mation and maturation by modulating NMDA receptor
function (Takasu et al., 2002). As the known range of bio-
logical functions performed by this multifaceted receptor/
ligand family is widening, focus is shifting to dissecting the
molecular mechanisms whereby these molecules transduce
such a variety of important signals into the cells.
Eph receptors, as other receptor tyrosine kinases (RTKs),
become phosphorylated at specific tyrosine residues in the
cytoplasmic domain after ligand binding. Phosphorylated
motifs serve as sites of interaction with certain cytoplasmic sig-
naling proteins (Songyang et al., 1993). Indeed, a variety of
SH2 domain–containing proteins have been identified as
EphB receptor binding partners, including the adaptor pro-
teins Crk, Grb10, SHEP-1, and SLAP, PI-3 kinase, and the
Ras GTPase-activating protein (Holland et al., 1997; Dodelet
et al., 1999). In previous work, we showed that activated
 
EphB1 recruits the adaptor protein Nck and the low molecular
weight phosphatase LMW-PTP through involvement of
Y594 and Y929 tyrosine residues (Stein et al., 1998a,b). We
demonstrated that EphB1 could discriminate ephrinB1 sur-
face density to direct integrin-mediated cell adhesion through
“inside-out” signaling (Huynh-Do et al., 1999). Furthermore,
we showed that the Ste20 kinase NIK (Nck-interacting kinase)
couples EphB1 to c-jun NH
 
2
 
-terminal kinase (JNK) and inte-
grin activation (Becker et al., 2000). Here we provide the first
evidence that ligand-activated EphB1 forms a signaling com-
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plex with c-Src kinase and p52
 
Shc
 
 adaptor protein to promote
extracellular signal–regulated kinase (ERK) 1/2 activation and
cell migration. Specifically we report that mutation of tyrosine
600 and 778 to phenylalanine impairs EphB1’s interaction
with c-Src and the p52
 
Shc
 
 phosphotyrosine binding (PTB) do-
main and thereby the subsequent ERK activation necessary
for chemotaxis.
 
Results
 
Activated EphB1 recruits the adaptor proteins 
Grb2 and p52
 
Shc
 
In the present study, we used P19, a murine cell line express-
ing endogenous EphB1, as well as CHO cells stably trans-
fected with EphB1 receptor (CHO-EphB1). We showed that
ligand stimulation of EphB1 resulted in its association with
the adaptor proteins Grb2 and p52
 
Shc
 
 (Fig. 1 A). Concomi-
tantly, EphB1 activation also increased Grb2 binding to
p52
 
Shc
 
 (Fig. 1 B), indicating that the Grb2 complex may be
recruited to EphB1 either directly or indirectly through
p52
 
Shc
 
. We also looked at the interaction between EphB1 and
Grb7, an adaptor protein recently shown to play an important
role in cell migration (Han et al., 2002). Grb7 also bound to
ligand-activated EphB1 (unpublished data). However, in con-
trast to the p52
 
Shc
 
–Grb2 interaction, we observed only a con-
stitutive association between p52
 
Shc
 
 and Grb7, without fur-
ther increase after EphB1 stimulation (Fig. 1 B).
The Src tyrosine kinase inhibitor PP2 inhibits p52
 
Shc
 
tyrosine phosphorylation, EphB1–p52
 
Shc
 
 interaction, and
p52
 
Shc
 
–Grb2 association. As Shc proteins can be substrates
either of activated RTKs or Src family kinases (SFKs), we
analyzed p52
 
Shc
 
 tyrosine phosphorylation status and its in-
teraction with Grb2 in the absence or presence of the SFK
inhibitor PP2. Time course analysis showed that p52
 
Shc
 
 tyro-
sine phosphorylation was an early event, taking place already
2 min after EphB1 activation (Fig. 1 C). In the presence of
PP2, EphB1-mediated tyrosine phosphorylation of p52
 
Shc
 
was partly reduced (Fig. 2 A), whereas EphB1 phosphor-
ylation was not affected (Fig. S1, available at http://www.
jcb.org/cgi/content/full/jcb.200302073/DC1). Pretreatment
with PP2 did not affect the EphB1–Grb2 association (Fig. 2
B) but prevented the EphB1–p52
 
Shc
 
 and p52
 
Shc
 
–Grb2 inter-
actions (Fig. 2 C). In aggregate, these results suggest that
ligand-stimulated EphB1 induces tyrosine phosphorylation
of p52
 
Shc
 
 through SFKs and at least another tyrosine kinase.
However, Src kinase–dependent tyrosine phosphorylation of
p52
 
Shc
 
 is necessary for its recruitment by EphB1 and its asso-
ciation with Grb2.
 
Ligand-stimulated EphB1 induces c-Src and 
ERK1/2 activation
 
We next asked whether c-Src itself would interact with acti-
vated EphB1. As shown in Fig. 3 A, c-Src is constitutively
bound to EphB1, however, the amount of EphB1-associated
Figure 1. Activated EphB1 associates with Grb2 and p52
Shc and induces tyrosine phosphorylation of p52
Shc. Serum-starved P19 (left) or 
CHO-EphB1 (right) were stimulated with 0.5–1  g/ml ephrinB2/Fc, and coimmunoprecipitations were performed as described in the Materials 
and methods. (A) Grb2 and p52
Shc immunoprecipitates were immunoblotted with anti-EphB1 or anti-HA, respectively. (B) p52
Shc immuno-
precipitates were immunoblotted with anti-Grb2 or anti-Grb7. (C) Time course of p52
Shc tyrosine phosphorylation. p52
Shc was immunoprecipitated 
with rabbit anti-Shc and immunoblotted with anti–PY20-HRP. Stripped blots were reprobed with anti-Shc. Blots are representative of at least 
three independent experiments.T
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Src protein clearly increases after ligand stimulation. Auto-
phosphorylation of c-Src at Y418 induces an active confor-
mation, whereas phosphorylation at Y527 by c-Src kinase re-
presses its kinase activity (Abram and Courtneidge, 2000).
Immunoblotting of cell lysates with an antibody specifically
recognizing Y418-phosphorylated c-Src showed a positive
signal within 5 min after ephrinB2/Fc stimulation (Fig. 3
B). Furthermore, Y418-phosphorylated c-Src is detected in
EphB1 immunoprecipitates from CHO-EphB1 cells, indi-
cating that this is the form of active c-Src bound to EphB1
(Fig. S2, available at http://www.jcb.org/cgi/content/full/
jcb.200302073/DC1). Together, these results identify c-Src
as a binding partner and downstream target of EphB1. As
SFKs have been proposed to function as intermediates be-
tween RTKs and MAPK/ERK to mediate mitogenesis and
cytoskeletal changes, we next investigated the effect of
ephrinB2/Fc on ERK1/2 activation. We had previously ob-
served in P19 cells a sustained JNK activation after EphB1
stimulation (Stein et al., 1998a). Using an antibody that rec-
ognizes the dually phosphorylated, active forms of ERK1/2
(p42/p44), we demonstrated that ephrinB2/Fc induced a
strong activation of ERK1/2 of 60- and 10-min duration for
P19 and CHO-EphB1 cells, respectively (Fig. 3 C). In the
same cellular context, EGF-dependent ERK1/2 activation
lasted only 10 and 5 min for P19 and CHO-EphB1, respec-
tively (unpublished data). EphB1-mediated ERK activation
was abrogated by the MEK inhibitor PD98059 and the Src
inhibitor PP2 (Fig. 3 D), but not by wortmannin, a PI-3 ki-
nase inhibitor (unpublished data). Together, these findings
confirm the central role played by c-Src in mediating ERK1/2
activation by ephrinB2/Fc.
 
ERK1/2 and c-Src mediate EphB1-dependent 
cell migration
 
In an effort to link these molecular events to biological end-
points, we next explored the role of ERK1/2 and c-Src on
cell adhesive and invasive behavior in response to EphB1
stimulation. In previous work, we used a wound closure as-
say to assess EphB1-dependent cellular chemokinesis (Huynh-
Do et al., 1999). Here, we extended these findings using a
modified Boyden chamber assay. Clustered ephrinB2/Fc
added to both lower and upper chambers induced a weak
chemokinetic response, whereas the most robust response
was observed with clustered ephrinB2/Fc added to the lower
chamber only: we showed a two- to threefold increase of
chemotaxis compared with the controls with vehicle or
IgG1. Dose–response experiments showed that optimal
responses were reached at concentrations of 0.5–1 
 
 
 
g/ml
for P19 cells and 1.5–3 
 
 
 
g/ml for CHO-EphB1 cells (un-
published data). Pretreatment with PD98059 or PP2 in-
 
Figure 2.
 
The Src tyrosine kinase inhibitor PP2 inhibits p52
 
Shc
 
 tyrosine phosphorylation, EphB1–p52
 
Shc
 
 interaction, and p52
 
Shc
 
–Grb2 association.
 
 
Serum-starved P19 (left) or CHO-EphB1 (right) were pretreated for 45 min with PP2 or PP3 (10 
 
 
 
M) before ephrinB2/Fc stimulation as 
described in the Materials and methods. (A) p52
 
Shc
 
 were immunoprecipitated with rabbit anti-Shc and immunoblotted with anti–PY20-HRP. 
To ensure that the same amount of protein has been immunoprecipitated, stripped blots were reprobed with anti-Shc. (B) After stimulation 
with 0.5–1 
 
 
 
g/ml ephrinB2/Fc for 10 min, cells were lysed in coimmunoprecipitation buffer (Materials and methods). Lysates were equally 
divised, and immunoprecipitations were performed with polyclonal anti-Shc or Grb2. Immunoprecipitates were immunoblotted with anti-EphB1 
or anti-HA. (C) p52
 
Shc
 
 was immunoprecipitated with rabbit anti-Shc and immunoblotted with anti-Grb2. Blots are representative of at least 
three independent experiments.T
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hibited ephrinB2/Fc-dependent chemotaxis (Fig. 4 A) but
had no effect on cell migration after serum stimulation (un-
published data). In sharp contrast, the increase of cell adhe-
sion in response to ephrinB2/Fc was unaffected by ERK and
c-Src inhibition (Fig. 4 B). Transfecting CHO cells with
dominant-negative EphB1-Y594F, which we previously
showed to block EphB1–Nck interaction as well as JNK ac-
tivation (Stein et al., 1998a; Becker et al., 2000), impaired
not only cell adhesion but also cell migration (Fig. 4 C).
These results support a model whereby EphB1-induced cell
adhesion is mainly dependent on JNK, whereas cell migra-
tory responses require the concerted action of both ERK1/2
and JNK.
 
Activated EphB1 recruits c-Src and p52
 
Shc
 
 and 
stimulates ERK1/2 to promote chemotaxis in primary 
human renal microvascular endothelial cells
 
So far, all the data presented here were generated either
in CHO-EphB1 cells or P19 cells expressing endogenous
EphB1. Indeed, we have validated the P19 system in previ-
ous work, showing similar biochemical and functional re-
sults when compared with primary endothelial cells. For ex-
ample, Stein et al. (1998b) demonstrated that in both P19
and human renal microvascular endothelial cells (HRMECs)
expressing high levels of EphB1, EphB1 receptor discrimi-
nates between different oligomeric forms of ephrinB1/Fc to
determine alternative signaling complexes, attachment, and
assembly responses. While this manuscript was in prepara-
tion, another group (Han et al., 2002) used P19 and CHO
cells transfected with EphB1 to show, independently from
us, that activated EphB1 associates with the adaptor protein
Grb7. Here, we further confirm the biological significance
of our results by placing them into the context of a primary
cell system. Fig. 5 (A and B) shows tyrosine phosphorylation
of p52
 
Shc
 
 as well as coimmunoprecipitation between EphB1
and, respectively, Shc and c-Src in response to stimulation of
HRMECs with ephrinB2/Fc. In agreement with our
previous findings, ephrinB2/Fc induced an activation of
ERK1/2, which was maximal at 15–20 min (unpublished
data) and was abrogated by PD98059 or PP2 (Fig. 5 C).
Pretreatment of HRMECs with the same inhibitors strongly
impaired ephrinB2-dependent migration but not adhesion
(Fig. 5 D).
With the exception of the recent work from Pratt and
Kinch (2002), most of the studies published to date have
shown a down-regulation of the ERK1/2 pathway by ligand-
stimulated EphA2 or EphB2. Eph receptors have also been
shown to negatively regulate the activation of ERK1/2
by some other growth factors (Elowe et al., 2001; Miao
et al., 2001). We therefore asked whether in the case of
EphB1, adhesion-induced activation of ERK1/2 could also be
blocked by ephrinB2/Fc, as in NG108 cells stably trans-
fected with EphB2 (Elowe et al., 2001). As shown in Fig.
S3 (top; available at http://www.jcb.org/cgi/content/full/
jcb.200302073/DC1), plating of CHO-EphB1 cells on fi-
bronectin led to a weak, but constant, increase of ERK1/2,
which was clearly potentiated at 5 and 60 min by low con-
centrations of ephrinB2/Fc. EphrinB2/Fc also increased in-
tegrin-induced ERK1/2 activation in P19, although to a
lesser extent (unpublished data). This biphasic (but not sus-
tained) potentiation of ERK1/2 by EphB1 is striking. The
early peak at 5 min is most probably due to ERK1/2 stimu-
lation by both ephrinB2/Fc and integrin activation. Pres-
ently, however, we can only speculate on the biological sig-
nificance of the second peak, which could be triggered by
various cytoskeletal modifications taking place during the
Figure 3. Activated EphB1 recruits 
c-Src and induces c-Src and ERK1/2 
activation. Serum-starved P19 (left) or 
CHO-EphB1 (right) were stimulated as 
described for the indicated times. (A) c-Src 
immunoprecipitates were immunoblotted 
with anti-EphB1 or anti-HA. (B) Time 
course of c-Src activation. 40  g of 
lysate was immunoblotted with an anti-
body recognizing Y418-phosphorylated 
Src. Stripped blots were reprobed with 
anti–c-Src. (C) Time course of ERK1/2 
activation. 40  g of lysate was immuno-
blotted with an antibody recognizing the 
dually phosphorylated, active forms of 
ERK1/2 (p42/p44). Stripped blots were 
reprobed with anti-ERK1/2. (D) For inhi-
bition experiments, cells were pretreated 
for 45 min with PD98509 (20  M), PP2, 
or PP3 (10  M) before stimulation with 
ephrinB2/Fc, and cell lysates were im-
munoblotted with anti–phospho-ERK1/2. 
Stripped blots were reprobed with anti-
ERK1/2. Blots are representative of at 
least three independent experiments.T
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complex process of cell migration. In primary HRMECs
(Fig. S3, bottom), ephrinB2/Fc was not able to further po-
tentiate the robust ERK activation induced by VEGF; how-
ever, we also could not see the inhibition described by Miao
et al. (2001) in bovine aortic endothelial cells.
 
Dominant-negative c-Src inhibits EphB1-dependent 
ERK activation and cell migration
 
To dissect the role of c-Src in EphB1 signaling, we next per-
formed a series of dominant-negative experiments. As shown
in Fig. 6 A, transfection of kinase-dead (K295R) or domi-
nant-negative c-Src (K295R/Y527F) inhibited the recruit-
ment of p52
 
Shc
 
 by ligand-stimulated EphB1. Cells trans-
fected with mutant c-Src displayed a 60–70% reduction of
ERK1/2 activation after exposure to ephrinB2/Fc (Fig. 6 B).
CHO-EphB1 transfected with increasing amounts of mu-
tant c-Src cDNA displayed a significantly decreased migra-
tory response to ephrinB2/Fc (Fig. 6 C). In contrast to the
abrogation of ERK activity in PP2-pretreated cells, the 60–
70% inhibition attained with mutant c-Src is consistent
with the previously observed functional redundancy among
different SFKs. For example, Stein et al. (1994) showed that
in some cell types, these kinases are able to compensate for
the loss of the other related kinases. Therefore, using two in-
dependent methods (i.e., Src kinase inhibitor and domi-
nant-negative c-Src), we demonstrated a requirement for
c-Src in EphB1-mediated ERK activation and cell migration.
 
EphB1 associates with c-Src and the Shc PTB domain 
through tyrosines Y600 and Y778
 
The cytoplasmic region of all Eph receptors contains several
conserved phosphorylated tyrosine residues. Sequence analy-
sis of EphB1 revealed that Y594 and Y600 are located in a
region highly conserved in the Eph receptor family. The se-
quence motifs surrounding these tyrosines, Y
 
594
 
IDP and
Y
 
600
 
EDP, correspond to high affinity Src family binding
motifs (Songyang et al., 1993; Ellis et al., 1996). We previ-
ously showed that Y594 in EphB1 binds to the SH2 domain
Figure 4. ERK1/2 and c-Src mediate EphB1-
dependent cell migration but not adhesion. Cell 
migration and adhesion were performed on P19 
(left) or CHO-EphB1 (right) as described in the 
Materials and methods. For migration assays (A), 
cells were seeded on the top chamber of fibronectin-
coated Transwell inserts. 1–2  g/ml clustered 
ephrinB2/Fc ( ) or human IgG1 was added to the 
lower chamber. In control experiments for random 
migration, clustered ephrinB2/Fc was added to the 
lower and upper chambers ( / ). Then cells were 
allowed to migrate to the underside for 6 h at 37 C. 
Migrated cells were fixed with glutaraldehyde, 
stained with crystal violet, and quantified by OD 
reading at 570 nm. For attachment assays (B), cells 
were seeded on 48-well plates coated with fibro-
nectin, in the presence of either ephrinB2/Fc or 
human IgG1 (300 ng/cm
2). After 30 min, adherent 
cells were fixed with glutaraldehyde, stained with 
crystal violet, and quantified by OD reading at 570 
nm. For inhibition experiments, cells were pre-
treated for 45 min with PD98509 (20  M) or PP2 
(10  M). (C) CHO cells were transiently trans-
fected with vector control (psR ), EphB1-WT,
or EphB1-Y594F. Adhesion and migration assays 
in response to ephrinB2/Fc were performed as 
described 48 h after transfection. Results are repre-
sentative of at least five independent experiments 
and represent the mean of triplicate wells   SEM. 
**, P   0.01; ***, P   0.001.T
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of Nck and is essential for JNK and integrin activation by
EphB1 (Stein et al., 1998a; Huynh-Do et al., 1999). To
evaluate the role of Y594 and Y600 in Src binding, we pre-
formed site-directed mutagenesis experiments. A single sub-
stitution, Y600F, disrupted the interaction between EphB1
and c-Src (Fig. 7 A) in transiently transfected CHO cells,
whereas Y594F appears not be required for the interaction
(Fig. S4, top, available at http://www.jcb.org/cgi/content/
full/jcb.200302073/DC1). Furthermore, EphB1-Y600F
also loses the ability to associate with p52
 
Shc
 
, a finding cor-
roborating our inhibition experiments with PP2 and imply-
ing that phosphorylation of p52
 
Shc
 
 by c-Src is necessary for
its recruitment to EphB1 signaling complexes (Fig. 7 B).
The adaptor protein Shc contains an SH2 domain at its
COOH terminus and a PTB domain at its NH
 
2
 
 terminus.
The PTB domain binds phosphotyrosine-containing pro-
teins, including activated receptor kinases. In vitro binding
experiments have indicated that the Shc PTB domain associ-
ates with activated EGF and NGF receptors (for review see
van der Geer and Pawson, 1995). Using a phosphotyrosine
peptide library, Songyang et al. (1995) demonstrated that
the Shc PTB domain recognizes preferentially pTyr in the
context NPXpY. Although this motif showed the strongest
selectivity for Asn at the pTyr
 
 
 
3
 
, according to their peptide
library prediction, Asp at pTyr
 
 
 
3
 
 ranked second behind Asn.
Examination of the cytoplasmic domain of EphB1 allowed
us to identify tyrosine 778, located in the sequence DPTY,
as a putative Shc PTB domain binding site. Indeed we ob-
served that the mutation Y778F inhibited the recruitment of
p52
 
Shc
 
 by activated EphB1 (Fig. 7 C). To confirm the in-
volvement of the Shc PTB domain, we performed in vitro
binding assays: GST fusion proteins containing the PTB do-
main of Shc (GST–Shc PTB) bound to activated EphB1 but
not to EphB1-Y778F (Fig. 7 D).
 
EphB1-dependent ERK activation and chemotaxis 
require Y600 and Y778
 
In view of these findings, we next assessed the roles of Y600
and Y778 in mediating ERK activation and cell migration.
Indeed, EphB1-induced ERK activation was strongly re-
duced in CHO cells expressing mutant EphB1-Y600F and
EphB1-Y778F (Fig. 8 A, bottom), whereas the expression
level or the tyrosine phosphorylation status of EphB1 re-
mained unchanged (Fig. 8 A, top). In contrast, EphB1-
Y594F, which was capable to recruit c-Src, retained the abil-
ity to induce ERK activation upon ephrinB2/Fc stimulation
Figure 5. Activated EphB1 recruits c-Src and p52
Shc and stimulates ERK1/2 to promote chemotaxis in primary HRMECs. Serum-starved 
HRMECs were incubated with 0.5 mM suramin for 6–8 h. After suramin washout, cells were stimulated with 0.5–1  g/ml ephrinB2/Fc for 15 min. 
(A) p52
Shc was immunoprecipitated with rabbit anti-Shc and immunoblotted with anti–PY20-HRP. Stripped blots were reprobed with anti-Shc. 
(B, left) p52
Shc was immunoprecipitated with rabbit anti-Shc and immunoblotted with anti-EphB1. Stripped blots were reprobed with anti-Shc. 
(B, right) c-Src immunoprecipitates were immunoblotted with anti-EphB1. Stripped blots were reprobed with anti–c-Src. (C) Cells were pre-
treated for 45 min with PD98509 (20  M), PP2, or PP3 (10  M) before stimulation with ephrinB2/Fc. 40  g of lysate was immunoblotted 
with an antibody recognizing the dually phosphorylated, active forms of ERK1/2 (p42/p44). Stripped blots were reprobed with anti-ERK1/2. 
(D) Cell migration and adhesion were performed on HRMECs as described in the Materials and methods. For inhibition experiments, cells 
were pretreated for 45 min with PD98509 (20  M) or PP2 (10  M). Results are representative of at least three independent experiments and 
represent the mean of triplicate wells   SEM. **, P   0.01; ***, P   0.001.T
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(Fig. S4, bottom). Finally, in CHO cells transiently trans-
fected with mutant EphB1-Y600F and EphB1-Y778F, we
observed a clear inhibition of migratory responses after
ephrinB2/Fc stimulation (Fig. 8 B). Taken together, these
results demonstrate that Y600 and Y778 are indispensable
for the recruitment of c-Src and p52
 
Shc
 
 to EphB1 signaling
complexes, and thus are important regulators of EphB1-
dependent ERK activation and cell migration.
 
Discussion
 
The intracellular signaling pathways mediating the biologi-
cal effects of Eph receptors and ephrins are only starting to
emerge. Although a plethora of proteins binding to the cyto-
plasmic domains of Eph receptors and ephrins has been
identified, their function in regulating angiogenesis, axonal
guidance, and topographic mapping in the developing em-
bryo are still poorly understood. MAPKs are major signaling
enzymes by which cells transduce extracellular stimuli to
regulate intricate intracellular processes; however, the actual
roles of each MAPK module are highly cell type and context
specific. In previous studies, we showed that the Nck–Nck-
interacting kinase (NIK)–JNK cascade modulates cell adhe-
sion in response to EphB1 activation (Stein et al., 1998a;
Becker et al., 2000). In the present work, using three cellular
systems expressing endogenous or stably transfected EphB1,
we provide evidences that the MAPK/ERK cascade plays a
crucial role in EphB1-dependent cell migration. We found a
strong activation of ERK1/2 in response to EphB1 stimula-
tion and identified key molecules linking EphB1 to ERK1/2
activation. First we showed that activated EphB1 recruits
Grb2 either directly or through the intermediary of the
adaptor protein p52
 
Shc
 
. We demonstrated that tyrosine
phosphorylation of p52
 
Shc
 
 by SFKs is a prerequisite for its as-
sociation with EphB1, on the one hand, and for recruitment
of Grb2, on the other hand. Finally, we identified c-Src itself
as an important target of EphB1, as ligand-stimulated
EphB1 recruits c-Src and induces its active conformation by
phosphorylation of tyrosine Y418.
In recent years, Src has emerged as a key molecule mediat-
ing specific angiogenic processes. Eliceiri et al. (1999)
demonstrated that dominant-negative Src mutants blocked
VEGF- but not bFGF-induced angiogenesis. Recently,
Palmer et al. (2002) nicely showed that SFKs are positive
regulators of ephrinB tyrosine phosphorylation and eph-
rinB-mediated angiogenic responses in endothelial cells. An
association between Eph receptors and SFKs has also been
reported in a number of studies. For example, Zisch et al.
(1998) showed in vitro binding of c-Src to Y611 of EphB2
and found tyrosine-phosphorylated EphB2 in Src immuno-
precipitates from COS cells transfected with both EphB2
and Src. Using the same approach, i.e., in vitro binding
assays and coimmunoprecipitation from transfected cells,
Hock et al. (1998) showed that Fyn associates with activated
EphB3 in an SH2-dependent manner. So far, however,
these studies have not clearly defined the precise role of
SFKs in mediating angiogenic processes downstream of Eph
receptors. The data presented here not only substantiate
these findings by placing them into the physiological context
of endogenous EphB1 and c-Src proteins, but also link c-Src
Figure 6. Dominant-negative c-Src significantly reduces EphB1-dependent ERK1/2 activation and cell migration. CHO-EphB1 transiently 
transfected with kinase-dead (K295R) or dominant-negative (K295R/Y527F) c-Src were stimulated as described with 1  g/ml ephrinB2/Fc. 
(A) p52
Shc immunoprecipitates were immunoblotted with anti-HA. (B) Cell lysates were immunoblotted with anti–phospho-ERK1/2. Stripped 
blots were reprobed with anti-ERK1/2 and, to confirm similar transfection efficiency, with anti–c-Src (not depicted). Blots are representative of 
at least three independent experiments. (C) CHO-EphB1 were transiently transfected with either 4 or 8  g of kinase-dead or dominant-negative 
c-Src, and migration assays were performed 48 h after transfection as described in the Materials and methods. Results are representative of at 
least three independent experiments and represent the mean of triplicate wells   SEM. **, P   0.01; ***, P   0.001.T
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activation to two important biological endpoints: EphB1-
dependent ERK activation and chemotaxis. In addition, our
mutational analysis strongly suggests that Y600 in EphB1 is
an important autophosphorylation site and the predominant
binding site for c-Src.
Activated c-Src can phosphorylate Shc on tyrosines to
provide docking sites for downstream signaling proteins. In
particular tyrosine-phosphorylated Shc is able to recruit
Grb2/SOS through association between the Grb2 SH2 do-
main and Shc phosphotyrosine residues (Pelicci et al., 1992;
Rozakis-Adcok et al., 1992), ultimately resulting in activa-
tion of the Ras–MAPK pathway. Our results demonstrate
that p52
Shc is a key substrate for c-Src after EphB1 ligand
stimulation and that its interaction with EphB1 is mediated
by phosphorylated Y778 of EphB1. Y778 is located within a
DPTY sequence, a motif that has been predicted by Song-
yang et al. (1995) as a putative Shc PTB domain binding se-
quence. To our knowledge, however, all the RTKs shown to
date to interact with Shc did so through the canonical se-
quence NPXpY. Our data thus provide new insight into the
binding specificities of the PTB domain of Shc. EphB1-
Y778F mutant was normally phosphorylated in response to
ephrinB2/Fc stimulation but failed to activate MAPK/ERK
and cell migration. These findings are consistent with the
experiments of Collins et al. (1999), which demonstrated by
mutational analysis that the PTB domain of Shc transduces
migratory signals while the SH2 domain is required for mi-
togenesis.
Interestingly, in the cellular systems we used, cell adhesion
was dependent on JNK (Stein et al., 1998a) but not on
ERK1/2 activity. On the other hand, our results showed
clearly that cell migration in response to EphB1 stimulation
required both the ERK1/2 and JNK pathways. To date,
studies on the role of Eph and ephrins on ERK activation
have yielded disparate results. We demonstrated that recep-
tor (EphB1) stimulation resulted in activation of both the
ERK and JNK pathways, whereas stimulation of its cognate
ligand (ephrinB1) activated only JNK (Huynh-Do et al.,
2002). Miao et al. (2000, 2001) found suppression of inte-
grin function and down-regulation of ERK1/2 after activa-
tion of EphA2 in prostate carcinoma cells. On the contrary,
in mouse fibroblastic cell lines, the ephrinA1–EphA2 system
promotes adhesion and actin cytoskeletal assembly in a
FAK- and p130cas-dependent manner (Carter et al., 2002).
Also, very recently, Pratt and Kinch (2002) found a stimula-
tion of the MAPK pathway by activated EphA2 in various
Figure 7. Functional analysis of EphB1-Y600F and EphB1-Y778F mutants in CHO cells. Cells were transiently transfected with EphB1-WT, 
EphB1-Y600F, or EphB1-Y778F as indicated and stimulated with ephrinB2/Fc, and coimmunoprecipitations were performed as described in 
the Materials and methods. Similar transfection efficiency was confirmed by probing lysates with anti-HA. (A) c-Src immunoprecipitates were 
immunoblotted with anti-HA. Stripped blots were reprobed with anti-c-Src. (B) p52
Shc immunoprecipitates were immunoblotted with anti-HA. 
Stripped blots were reprobed with anti-Shc. (C) p52
Shc immunoprecipitates were immunoblotted with anti-HA. Stripped blots were reprobed 
with anti-Shc. (D) GST pull-down assays. Cells were transfected and stimulated as described in the Materials and methods. 500  g of cleared 
lysate was incubated with purified GST (not depicted) or GST–Shc PTB for 2 h at 4 C. Pellets were washed three times in coimmunoprecipitation 
buffer, resuspended in SDS sample buffer, and resolved by 8% SDS-PAGE for HA–EphB1 expression. Results are representative of at least 
three independent experiments.T
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cell lines. Interestingly, this was also accompanied by the
formation of an EphA2–Shc–Grb2 molecular complex, as in
the case of EphB1. However the authors did not further
identify the amino acid residues involved in this process.
Recently Elowe et al. (2001) showed that down-regulation
of MAPK by ephrinB1/Fc was required for neurite retrac-
tion of NG108 cells stably transfected with EphB2. In-
versely, in a study by Davy and Robbins (2000), activation
of ephrinA5 induced sustained phosphorylation of ERK1/2
as well as increased cell adhesion.
These apparently contradictory findings could be ex-
plained by several, not mutually exclusive, scenarios. First,
the observed differences could result from the variable ex-
pression of each individual receptor–ligand pair on the sur-
face of a cell. We previously demonstrated that cellular adhe-
sion in response to EphB1 stimulation follows a biphasic
curve, depending on the surface density of encountered
ephrinB1 (Huynh-Do et al., 1999). In light of these results,
we propose that the cellular context (i.e., the different levels
of protein expression) determines the extent of receptor or
ligand clustering, which in turn would initiate either activa-
tion or inactivation of integrins. As the findings presented
here were essentially based on endogenous EphB1, we ex-
pect them to reflect real signaling processes initiated upon
juxtacrine contact.
In recent years, interactions between Eph and other cell
surface receptors have emerged as an important issue (Miao
et al., 2001; Takasu et al., 2002). In contrast to EphA2
and EphB2, which have been shown to negatively regulate
the ERK1/2 activation induced by some other growth fac-
tors, ligand stimulation of EphB1 receptor expressed in
primary HRMECs did not interfere with the robust ERK
activation in response to VEGF. Furthermore, ephrinB2/
Fc clearly potentiated the integrin-induced ERK1/2 activa-
tion in CHO-EphB1 or P19. At the present, we can only
speculate about possible mechanisms underlying these dis-
crepancies. On the one hand, endothelial cells from differ-
ent vascular lineages have been shown to display different
biological behaviors. For example, although HRMECs and
human umbilical venous endothelial cells (HUVECs) ex-
press both EphA2 and EphB1, HRMECs assemble into
capillary-like structures in response to ephrinB1/Fc, but
not ephrinA1/Fc, under conditions that promote HU-
VECs to assemble in response to ephrinA1/Fc but not
ephrinB1/Fc (Daniel et al., 1996). Furthermore it appears
that distinct Eph receptors can transmit opposite signals to
the MAPK pathways through their ability to engage dis-
tinct targets; thus, the variation between systems may well
reflect receptor cross-talk and/or different feedback loops.
Finally, as SFKs have now emerged as major regulators of
both Eph and ephrin signaling, we anticipate that the iden-
tification of the kinases and phosphatases responsible for
the phosphorylation of the Eph–ephrin system will be an
important step in molecularly dissecting these multiple sig-
naling pathways.
In summary, the observations reported here represent, to
our knowledge, the first demonstration of an activation of
the ERK1/2 pathway by a member of the EphB receptor
family. In addition, they shed new light on the precise
mechanism of c-Src activation downstream of EphB1 recep-
tor. Based on these data, we propose the following model
(Fig. 9). EphB1 engagement with its cognate ephrin ligands
induces rapid recruitment of c-Src through Y600 of EphB1.
Autophosphorylated c-Src then phosphorylates p52
Shc, al-
lowing binding of the Shc PTB domain to Y778 of EphB1.
The resulting activation of the MAPK cascade, in turn, trig-
gers all cellular events necessary for cytoskeletal rearrange-
ment and cell migration.
Figure 8. EphB1-Y600F and EphB1-Y778F mutants inhibit ERK activation and cell migration. (A) Cells were transiently transfected with 
EphB1-WT, EphB1-Y600F, or EphB1-Y778F and stimulated as described in the Materials and methods. (Top) EphB1 was immunoprecipitated 
with monoclonal anti-HA, and samples were divided and separated on two different gels. Immunoblotting was performed using 4G10–HRP 
(pY-EphB1) and anti-HA. (Bottom) Cell lysates were immunoblotted with anti–phospho-ERK1/2. Stripped blots were reprobed with anti-ERK1/2. 
(B) Cells were transiently transfected with EphB1-WT, EphB1-Y600F, or EphB1-Y778F. Migration assays in response to 1  g/ml clustered 
ephrinB2/Fc were performed 48 h after transfection. Results are representative of at least three independent experiments and represent the 
mean of triplicate wells   SEM. ***, P   0.001.T
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Our findings add one more piece to the Eph–ephrin puz-
zle: they provide a good model to study the dichotomy of
the JNK and ERK modules, confirming that multiple, inter-
connected signaling pathways underlie Eph receptor–medi-
ated changes in cytoskeletal organization and chemotaxis. As
both axonal guidance and angiogenesis are complex pro-
cesses that are crucial for survival, this versatility could be in-
terpreted as an important tool allowing fine tuning of the
cellular responses to a particular environment. As the list of
functions that involve Eph receptors and ephrins is growing,
further delineation of the roles of their effector molecules
will be of considerable value to the understanding of the mo-
lecular mechanisms whereby neural or endothelial cells regu-
late shape changes, movements, cell–matrix interactions,
and ultimately survival.
Materials and methods
Reagents
Cell culture reagents and fibronectin were from Life Technologies,
ephrinB2/Fc was from Immunex, human IgG1, suramin, and VEGF were
from Sigma-Aldrich, and PD98059, PP2, and PP3 were from Calbiochem.
The following antibodies were used for immunoprecipitation: rabbit anti-
Grb2 (Santa Cruz Biotechnology, Inc.) and rabbit anti-Shc and monoclonal
anti-Src (Upstate Biotechnology). The following antibodies were used for
immunoblotting: goat anti-EphB1 (R&D Systems), monoclonal anti-HA
(12CA5) (Boehringer), polyclonal anti–active MAPK (Promega), anti-ERK1/2
and anti–phosphotyrosine 4G10-HRP (Upstate Biotechnology), phospho-
specific Y418 anti-Src (Biosource International), and monoclonal anti-Grb2
(Transduction Laboratories). Rabbit anti-Grb7 was a gift from B. Margolis
(University of Michigan, Ann Arbor, MI). The ECL chemiluminescence kit
and ECL phosphorylation module anti–phosphotyrosine-HRP conjugate
were from Amersham Biosciences.
Generation of a cell line stably expressing EphB1–HA receptor
The previously described pSR -hEphB1-HA construct (Stein et al., 1998a)
was used to generate stably expressing CHO cell lines. Cells were trans-
fected with 4  g of the pSR -hEphB1-HA plasmid using LipoFECTAMINE
Plus (Life Technologies), following the manufacturer’s guidelines. CHO
cells expressing the hEphB1–HA construct were identified by flow cytome-
try (FACSCalibur
®; Becton Dickinson), using biotinylated ephrinB2/Fc and
streptavidin–FITC. Fluorescence-activated cell sorting was performed to
isolate different populations of cells expressing low, middle, or high levels
of hEphB1–HA. CHO-EphB1 cells used here expressed high levels of
EphB1–HA.
Site-directed mutagenesis
Mutagenesis was performed using the QuickChange site-directed mu-
tagenesis kit (Stratagene). PCRs were performed using an overlap extension
by Pfu DNA polymerase with pSR -hEphB1-HA plasmid as a template.
The oligonucleotides used to generate point mutations converting Y600
to F and Y778 to F were 5 -GACCCCTTCACTTTTGAGGATCCCAAC-
GAAGCTGTCCGG-3  (sense) and 5 -CCGGACAGCTTCGTTGGGATCCT-
CAAAAGTGAAAGGGGTC-3  (antisense), and 5 -CCAGGATGACACCT-
CAGATCCCACCTTCACCAGCTCCTT-3  (sense) and 5 -AAGGAGCTGGT-
GAAGGTGGGATCTGAGGTGTTCAT-3  (antisense), respectively. Mutations
were confirmed by nucleotide sequencing analysis. The pSR -hEphB1-
Y594F-HA plasmid has been previously described by Stein et al. (1998a).
Cell culture and transfection
P19 cells were cultured in  -MEM with 10% FCS, and CHO-EphB1 cells
were cultured in DME–F12 with 10% FCS containing Zeocin (Invitrogen).
Primary HRMECs were isolated and cultured as previously described (Stein
et al., 1998b) and used up to passage 7 or 8. For transient transfections,
CHO-EphB1 cells were seeded into 100-mm plates and incubated in cul-
ture medium for 24 h before transfection. Cells were transfected using Li-
poFECTAMINE Plus with 4 or 8  g of the indicated plasmids. Cotransfec-
tion of the plasmid pEGFP was used at 1  g/100-mm plate as a marker of
transfection efficiency ( 70%). Cells were used for biochemical or func-
tional assays 48 h later.
Western blots and immunoprecipitation
Cells were serum starved for 24 h (P19 and HRMEC) or 48 h (CHO-EphB1)
in Opti-MEM and then treated with 0.5 mM suramin for 3–8 h. Cells were
then rinsed twice with PBS and incubated in 1% BSA for 45–60 min before
stimulation for the indicated times at 37 C with 0.5–1  g/ml of ephrinB2/
Fc, control IgG1, or VEGF (10 ng/ml). For assessment of ERK1/2 activation
and c-Src tyrosine phosphorylation, cells were lysed in RIPA buffer
(Huynh-Do et al., 1999), and 40  g of protein was loaded on a 10% SDS-
PAGE. After transfer to Immobilon/PVDF membranes (Millipore), phos-
phorylated ERK1/2 or c-Src was detected with phosphospecific anti-ERK1/
2 or anti–phosphoY418-Src. Membranes were then stripped and reprobed
with anti-ERK1/2 or anti–c-Src. For coimmunoprecipitations, cells were
lysed in buffer containing 1% Triton X-100, 20 mM Hepes, pH 7.5, 150
mM NaCl, 10 mM NaF, 5 mM EDTA, 60 mM n-octyl-glucoside, supple-
mented with 1 mM orthovanadate and protease inhibitors. Immunoprecip-
itations were performed with the indicated antibodies for 2 h at 4 C as de-
scribed previously (Stein et al., 1998a).
Cell adhesion and migration
Attachment assays were performed as described previously (Huynh-Do et
al., 1999). For migration assays, a modified Boyden chamber system was
used. In brief, serum-starved cells were resuspended in Opti-MEM and
seeded on fibronectin-coated Transwell inserts with 8- M pore size mem-
branes (Costar). 1–2  g/ml clustered ephrinB2/Fc was added to either the
lower chamber alone ( , chemotaxis assay) or the lower and upper cham-
bers ( / , chemokinetic control), and then cells were left to migrate for
6 h at 37 C. Nonmigrating cells were removed with a cotton swab, and mi-
grated cells were fixed with glutaraldehyde, stained with 0.5% crystal vio-
let, and then eluted with acetic acid. Cell migration was quantified by
spectrophotometric reading at OD570.
Figure 9.  Proposed model of EphB1-dependent chemotaxis. 
Shown is a proposed model of the biochemical mechanisms of 
EphB1-dependent activation of the Src–ERK pathway. Ligand-
activated EphB1 recruits c-Src through Y600 of EphB1. Autophos-
phorylated c-Src (Y418-c-Src), in turn, phosphorylates p52
Shc, 
allowing binding of the Shc PTB domain to Y778 of EphB1. On the 
other hand, Grb2 is recruited either directly to EphB1 or through the 
intermediary of p52
Shc. The resulting activation of the ERK cascade 
triggers cell migration.T
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GST fusion protein pull-down assay
GST fusion proteins constructed in pGEX vectors were purified as previ-
ously described (Stein et al., 1998a). CHO cells transfected with EphB1-
WT or EphB1-Y778F were stimulated with ephrinB2/Fc and lysed as
described above. 500  g of cleared lysate was incubated with purified
GST–Shc PTB or GST control (not depicted) for 2 h at 4 C. Pellets were
washed three times in coimmunoprecipitation buffer, resuspended in SDS
sample buffer, and resolved by 8% SDS-PAGE for HA–EphB1 expression.
Statistical analysis
All values are presented as mean   SEM. Analysis of variance (ANOVA) t
test was used for statistical analysis, and differences were considered sig-
nificant when P   0.05. Unless indicated otherwise, data are from at least
three independent experiments.
Online supplemental material
The supplemental material (Figs. S1–S4) is available at http://www.jcb.org/
cgi/content/full/jcb.200302073/DC1. Fig. S1 shows that the Src tyrosine ki-
nase inhibitor PP2 does not inhibit tyrosine phosphorylation of EphB1. Fig.
S2 shows that ligand-stimulated EphB1 recruits Y418-phosphorylated
c-Src. Fig. S3 (top) shows that ephrinB2/Fc stimulation increases integrin-
induced ERK1/2 activation and (bottom) that ephrinB2/Fc stimulation does
not inhibit VEGF-induced ERK activation. Fig. S4 shows that EphB1-Y594
associates with c-Src (top) and stimulates MAPK/ERK (bottom).
Dominant-negative c-Src plasmid was provided by S. Roche (Centre Na-
tional de la Recherche Scientifique, Montpellier, France). pGEX-vectors
containing GST–Shc PTB and control were gifts from K. Ravichandran
(University of Virginia, Charlottesville, VA). We thank Drs. S. Hanks
(Vanderbilt University), B. Frey (University of Bern), and F. Frey (University
of Bern) for encouragement and comments on the manuscript. 
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